Assisted Reproductive Technology Market

Assisted Reproductive Technology Market Outlook (2022 to 2032)

The global assisted reproductive technology market is expected to be worth US$ 24.5 billion in fiscal year 2022, up from US$ 23 billion in fiscal year 2021. From 2022 to 2032, the market is expected to grow at a 6.2% CAGR, reaching a value of US$ 44.71 billion by the end of 2032.

Approximately 190 million people worldwide experience infertility-related issues, in accordance with the World Health Organization Statistics 2021. Numerous variables, such as the rise in cigarette smoking, sexually transmitted infections (STIs), instances of obesity, polycystic ovary syndrome (PCOS), endometriosis, primary ovarian insufficiency (POC), and others, might be blamed for the growing incidence of infertility.

The demand for ART treatments is anticipated to increase as society accepts ART more frequently as a result of the adoption of more sophisticated technologies, including such time-lapse embryo imaging, preimplantation genetic testing, magnetic activated cell sorting, and endometrial receptivity analysis testing.

For instance, the 2021 Fertility Clinic Success Rates Report from the Centers for Disease Control and Prevention (CDC) states that 474 fertility clinics in the United States performed about 340,889 ART treatments, resulting in 78,988 live births and 84,146 live-born children. Additionally, the sector is anticipated to develop as public knowledge of the factors that contribute to infertility and its treatments increases.

Many groups are collaborating to spread knowledge of infertility treatment alternatives, including the American Society for Reproductive Medicine as well as the Society for Assisted Reproductive Technology (SART). In the area of culture media for ART, several novel sorts of study are also being conducted.

For instance, Cooper Surgicals discovered that cell cultures containing Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) also contain crucial nutrients needed for embryogenesis and further improve the transmission between the endometrium and the embryo creating the necessary environment for the pregnancy.

Such developments in this domain are expected to soar up the demand for assisted reproductive technology market during the forecast period, 2022 to 2032.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 23 Billion
Expected Market Value (2022)	US$ 24.5 Billion
Projected Forecast Value (2032)	US$ 44.71 Billion
Global Growth Rate (2022 to 2032)	6.2%
Market share of Europe (2022)	38%
CAGR of US (2022 to 2032)	4.8%
Prominent Players in The Global Market	Cosmos Biomedical Ltd.; CooperSurgical, Inc.; Microm U.K. Ltd.; Cryolab Ltd.; Vitrolife AB; FUJIFILM Irvine Scientific; Bloom IVF Centre; Ferring B.V.; European Sperm Bank; Merck KGaA

2017 to 2021 Assisted Reproductive Technology Market Demand Analysis Vs. Forecast 2022 to 2032

According to market research and competitive intelligence provider Fact.MR- the assisted reproductive technology market generated US$ 23 billion at the conclusion of the 2017 to 2021 assessment period, growing at a CAGR of 4.5%.

Due to business closures and the ensuing drop in patient care levels, the pandemic had a detrimental effect on the sector. For instance, a substantial decrease in assisted reproductive technology (ART) treatments was observed in March and April 2020 when compared to 2019 owing to the concern of COVID-19 infection, in accordance with a research which has data on 290 million U.S. people.

Due to the restoration of consultation as well as treatment by the the European Society of Human Reproduction and Embryology (ESHRE), American Society for Reproductive Medicine, and the International Federation of Fertility Societies, the sector soon recovered and returned in the pre-pandemic levels.

Post-pandemic, technological improvement and telemedicine usage in the ART industry are predicted to drive market growth. Telehealth use in ART therapies is still in its early stages. Nonetheless, it has huge future potential due to benefits such as remote monitoring as well as continuous administration.

During the projected period, technological progress, new product development, and strategic acquisitions and mergers by key players are likely to drive market expansion. CooperCompanies, for example, completed its acquisition of Generate Life Sciences in December 2021.

Generate Life Sciences is the world's leading provider of donor eggs and sperm for reproductive treatments. The USD 1.6 billion purchase is likely to benefit CooperCompanies' fertility products. Such developments are expected to boost the global demand during the forecast period.

Prominent Growth Drivers Influencing Assisted Reproductive Technology Market

Higher rates of infertility is going to propel the global market demand

The prevalence of infertility caused by stressed lives, drug addiction, delayed marriages, obesity, smoking, high junk food consumption, alcoholism, and other conditions is the main factor pushing the use of assisted reproductive technology (ART).

Infertility rates are greater in North Africa, Eastern Europe, and the Middle East, for example, where they are 11% of women who had a prior live birth as well as 2% of women aged 21 to 44 who didn't have any live births at all, in accordance with a study on female infertility.

As a result, the market for assisted reproductive technologies is anticipated to grow throughout time as a result of the increased infertility. The market for assisted reproductive technology is anticipated to grow in the future as a result of the aforementioned causes.

The increasing notions of single parenting and same-sex marriage is expected to boost the global growth

Over the course of the projected timeframe, the market for assisted reproductive technologies is anticipated to develop significantly due to the rising number of single parent families, increased awareness of same-sex unions, and other factors.

According to the Human Rights Campaign (HRC) Foundation's 2022 report, for instance, there are already 32 countries where the same-sex marriage is legal, and more are projected to follow since legal or parliamentary processes are ongoing in several other nations. Thus, it is anticipated that as the number of same-sex partnerships rises, so will the need for ART procedures, which would spur market expansion.

As a result of the aforementioned factors, the market for assisted reproductive technologies (ART) is anticipated to expand throughout the course of the projected period.

What Could Possibly Hinder Assisted Reproductive Technology Market Demand?

Multifetal pregnancy and its anticipated effects can hinder the global market growth

Significantly greater multifetal pregnancy might happen in conjunction with ART as well as ovulation induction. One main threat of ART along with the ovulation induction is the multifetal pregnancy and its results that come along with it, hence it is imperative that a singleton gestation be attained.

Following professional organization recommendations for the number of eggs to be transferred, such as those issued by the American Society for Reproductive Medicine (ASRM), and striving to promote and increase the utilization of single-embryo transfer are a few of these initiatives.

The dangers of multifetal gestation with any of these methods should be discussed with patients and couples. Such a discussion causes many couples to step back and hence hinders the growth of the global ART market.

The possibility of multifetal reduction should be explored if a higher-order (in case of a triplet or more) multifetal pregnancy is discovered. If a higher-order multifetal pregnancy is still occurring, continued obstetric treatment should be received from a gynecologist or other obstetric care provider in a setting equipped to handle potential risks and consequences. These kinds of risk factors can impede the global growth of the ART market.

Category-wise Insights

Which procedure type is gaining traction in the global market?

Fresh non-donor fertility procedures are considered to be especially suitable

In the year 2022, the fresh non-donor fertility procedures are expected to occupy a 54% of the global market share. The reproductive systems of men as well as women are being negatively impacted by demanding lifestyles, including mental stress.

The main motivation for utilizing fresh non-donor ova in ART cycles, according to the Centers for Disease Control and Prevention (CDC), is the desire to have a child utilizing one's own eggs. The use of fresh non-donor eggs is becoming increasingly popular, especially among the women under the age of 35 years.

For women who have a high risk of being infertile, medical practitioners advise medical egg preservation due to delayed planning of a child and the rising effect of chronic conditions like cancer.

The market for frozen non-donor methods is anticipated to rise as major organizations take steps to assist employees with their infertility concerns through rewards and incentives based on egg preservation. For instance, Facebook Inc. and Apple Inc. have started programmes that provide female employees extra benefits to save their eggs. Such developments are going to boost the demand for the ART at the global level during 2022 to 2032.

Which end-use facility will be using these treatments more often?

Fertility clinics are doing well in the market for assisted reproduction technologies

The fertility clinic is anticipated to experience a CAGR of 6.4% from 2022 to 2032. Multiple treatment sessions of infertility therapy utilizing assisted reproductive technology make the procedure extremely costly. Fertility clinics are increasing their emphasis on providing one-stop shopping for everything from diagnosis to therapy.

Separate semen as well as embryology labs have also been developed to guarantee a pathogen-free, stable, and non-toxic atmosphere for gamete handling.

The priority of fertility clinic medical professionals has been on providing excellent patient service by harnessing new technology, which is increasing demands for neoteric equipment as well as gadgets from reproductive clinics. Taking these factors into account, fertility clinics are expected to contribute roughly US$ 17.1 billion in revenue to the assisted reproductive technology market in 2022, which is the most when contrasted to hospitals and centers providing comparable services.

Country Insights

What is the Market Outlook for Assisted Reproductive Technologies in Europe?

Rising rates of infertility are driving the demand

Europe dominated the assisted reproductive technology market with a revenue share of 38%. The high percentage is attributed to an increase in the rate of infertility, more excellent knowledge of fertility treatments, technological advancements, and encouraging government programs.

Modern technology and top-notch fertility treatment services work together to create a favorable environment for developing the European market. During the forecast period, such developments will fuel The European assisted reproductive technology market growth.

What Can Be Anticipated From The Assisted Reproductive Technology Market In North America?

Emerging economies' contribution to a more robust regional market over the forecast period. The U.S. assisted reproductive technology market is anticipated to grow significantly during the forecasted period. The increase, anticipated to produce a steady CAGR during the forecast period (2022 to 2032), can be attributed to the excellent results reported by patients receiving treatment.

The United States market is anticipated to grow during the forecast period as a result of technological advancements and increased assisted reproductive technology research. Additionally, new product introductions and technical developments in ART technology are anticipated to fuel assisted reproductive technology market growth.

Heavy Oil for Embryo Culture, a sterilized mineral oil with the proper weight viscosity that offers the ideal balance of ease of application and safety for IVF laboratories, was introduced by FUJIFILM Irvine Scientific, Inc. in June 2022. During the forecast period, such events will dramatically accelerate segmental growth in the United States assisted reproductive technology market.

What is to be expected from the Asia Pacific Market for Assisted Reproductive Technology?

The Asia Pacific region is anticipated to grow as a result of the emerging assisted reproductive technology market in some nations, including China, Korea, and Japan. Due to the rapidly rising prevalence of infertility and the declining socio-ethical stigma among the populace, Japan is predicted to have a higher CAGR by the end of 2032. The World Health Organization (WHO) estimates a range of 3.9% to 16.8% for the prevalence of primary infertility in India.

Over the forecast period, rising disposable income and increased use of technologically advanced services are likely to fuel Korea's demand for assisted reproductive technology services. Due to the rapidly rising prevalence of infertility and lower socio-ethical stigma among the populace, Korea is predicted to grow more quickly. The market in Korea is anticipated to grow rapidly due to technological developments and increased assisted reproductive technology research.

Start-up Scenario

The number of businesses entering the reproductive market has increased, affecting everything from the hardware as well as diagnostics to community-driven mobile applications and monitoring apps, according to the many firms in this industry.

• A medical device firm called Fertility creates cutting-edge gadgets to assist couples in having children at home. It introduced a conception cup, a high-quality, hormone-free conceiving aid that boosts a woman's probability of getting pregnant by up to 48%. Without progressing to the more intrusive IVF stage, Fertility can serve as the platform for non- to noninvasive at-home reproductive care, saving enormous expenditures for both couples as well as insurance providers.
• Wawa is a technology platform that uses the biggest and most varied dataset produced by patients to gather real-world evidence for infertility therapy. The dataset examines tens of thousands of patient treatment cycles, mental health conditions, symptom patterns, and many other factors in order to spot trends and offer therapeutic decision assistance for better results. Wawa may become the software for infertility treatment by gathering and organizing infertility data, then using machine learning to analyze the largest infertility database.

Competitive Landscape

To increase their market share, major companies are implementing a variety of measures, including new launches, R&D spending, and product portfolio growth.

• CooperSurgical bought Embryo Options, a well-known provider of cryo-storage software for reproductive clinics, in January 2021. Patients will benefit from Embryo Options platform by having access to its online resources, which will inform them about stored specimens for next ART treatment cycles.
• IVFTECH ApS (IVFtech) and its affiliated company, K4 Technology ApS, were purchased by Hamilton Throne Ltd., a global supplier of ART research, in July 2021. With the help of its affiliated company, K4, IVFtech is committed to offering laminar flow workstations and large-capacity incubators for ART. The acquisition cost 8 million USD.

Key Segments Covered In The Assisted Reproductive Technology Market Report

• By Procedure :

  • Frozen Donor
  • Frozen Non-donor
  • Fresh Donor
  • Fresh Non-donor
  • Embryo Banking

• By Technology :

  • In-vitro Fertilization
    • Intracytoplasmic Sperm Injection (ICSI)
    • Preimplantation Genetic Diagnosis (PGD)
  • Surrogacy
  • Artificial Insemination
    • Intrauterine Insemination (IUI)
    • Intracervical Insemination (ICI)
    • Others
  • Others

• By End User :

  • Fertility Clinics
  • Hospitals
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa